Generali Asset Management SPA SGR Cuts Stake in Humana Inc. $HUM

Generali Asset Management SPA SGR lowered its stake in shares of Humana Inc. (NYSE:HUM) by 10.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,668 shares of the insurance provider’s stock after selling 930 shares during the period. Generali Asset Management SPA SGR’s holdings in Humana were worth $1,875,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after purchasing an additional 1,143,662 shares in the last quarter. Dodge & Cox increased its stake in shares of Humana by 5.5% during the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock worth $2,845,830,000 after purchasing an additional 557,175 shares in the last quarter. Pzena Investment Management LLC increased its stake in shares of Humana by 6.5% during the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock worth $996,664,000 after purchasing an additional 247,744 shares in the last quarter. Davis Selected Advisers increased its stake in shares of Humana by 3.3% during the first quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock worth $616,873,000 after purchasing an additional 74,434 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC increased its stake in shares of Humana by 1.6% during the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider’s stock worth $327,293,000 after purchasing an additional 19,613 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

NYSE:HUM opened at $266.78 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The firm has a market capitalization of $32.09 billion, a price-to-earnings ratio of 20.47, a PEG ratio of 1.53 and a beta of 0.42. The company’s 50-day moving average is $280.37 and its two-hundred day moving average is $258.16. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana’s dividend payout ratio is currently 27.17%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Barclays cut their target price on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research note on Friday, October 3rd. Bank of America increased their price objective on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a report on Friday, October 10th. Sanford C. Bernstein increased their price objective on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Guggenheim reiterated a “buy” rating on shares of Humana in a report on Friday, October 3rd. Finally, Wall Street Zen downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $297.58.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.